64Z Stock Overview
A biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Keymed Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.80 |
| 52 Week High | HK$5.45 |
| 52 Week Low | HK$3.24 |
| Beta | -0.060 |
| 1 Month Change | -19.83% |
| 3 Month Change | -12.04% |
| 1 Year Change | -30.28% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 52.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 64Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.1% | 1.2% | -0.3% |
| 1Y | -30.3% | -14.3% | 7.0% |
Return vs Industry: 64Z underperformed the German Biotechs industry which returned -14.3% over the past year.
Return vs Market: 64Z underperformed the German Market which returned 7% over the past year.
Price Volatility
| 64Z volatility | |
|---|---|
| 64Z Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 64Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 64Z's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,116 | Bo Chen | www.keymedbio.com |
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD.
Keymed Biosciences Inc. Fundamentals Summary
| 64Z fundamental statistics | |
|---|---|
| Market cap | €1.08b |
| Earnings (TTM) | -€97.83m |
| Revenue (TTM) | €10.75m |
100.7x
P/S Ratio-11.1x
P/E RatioIs 64Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 64Z income statement (TTM) | |
|---|---|
| Revenue | CN¥81.65m |
| Cost of Revenue | CN¥25.60m |
| Gross Profit | CN¥56.06m |
| Other Expenses | CN¥799.13m |
| Earnings | -CN¥743.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70 |
| Gross Margin | 68.65% |
| Net Profit Margin | -910.03% |
| Debt/Equity Ratio | 27.3% |
How did 64Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 15:06 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Keymed Biosciences Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Wangbin Zhou | China International Capital Corporation Limited |